Rallybio posts Q3 net income of $16 million
Rallybio Corporation reported a Q3 net income of $16 million, or $0.36 per share, a turnaround from a net loss of $11.5 million in Q3 2024. As of September 30, 2025, the company had $59.3 million in cash and marketable securities. Rallybio generated $20 million from selling its interest in REV102 to Recursion Pharmaceuticals and advanced its lead program, RLYB116, completing dosing in Cohort 1 of its Phase 1 study, with data from Cohort 2 expected in Q4 2025.
Rallybio Corporation reported a net income of $16.0 million, or $0.36 per common share, for the third quarter of 2025, compared to a net loss of $11.5 million, or $0.26 per common share, for the same period in 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $59.3 million. During the quarter, Rallybio generated $20.0 million from the sale of its interest in REV102 to Recursion Pharmaceuticals. The company advanced its lead program, RLYB116, with the completion of dosing in Cohort 1 of its confirmatory Phase 1 study, and expects to report data from the second cohort in the fourth quarter of 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105235045) on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
